Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × nirogacestat × 1 year × Clear all
NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting
208 enrolled 5 charts
Plasma cell

Multiple Myeloma

NCT07084896 2026-05-06

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Active not recruiting
106 enrolled 32 charts
Plasma cell

Multiple Myeloma

NCT05090566 2026-04-24

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Pfizer

Phase 2 Terminated
46 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡